GL1X · GenesisL1 explorer

MolNFT v1 · #101369 · protein

Clostridium difficile toxin B crop domain in complex with Fab domains of neutralizing antibody bezlotoxumab

4NP4: “Clostridium difficile toxin B crop domain in complex with Fab domains of neutralizing antibody bezlotoxumab”. X-ray diffraction, 14 pockets (best druggability 0.66). MolNFT v1 #101369 on GenesisL1: 3D structure, binding sites and…

PDB
4NP4
Type
protein
Length
1,133 residues
Chains
5
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Toxin B; Bezlotoxumab heavy chain; Bezlotoxumab light chain
UniProt
P18177
Pockets
14 · best druggability 0.66

Structure

x-ray diffraction · 4 distinct chains · 4% helix, 52% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AToxin Bprotein2710% helix, 52% strandP18177
HBezlotoxumab heavy chainprotein2156% helix, 52% strand—
IBezlotoxumab heavy chainprotein2215% helix, 50% strand—
L, MBezlotoxumab light chainprotein2136% helix, 54% strand—

Pockets

14 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16970.660.7561empty
2670.550.8824empty
33840.540.7348empty
42180.460.7432empty
51890.440.7425empty

Interfaces

9 interfaces between chains.

  • H–L · 1815 Ų buried · 13 hydrogen bonds · protein-protein
  • I–M · 1740 Ų buried · 14 hydrogen bonds · protein-protein
  • A–H · 717 Ų buried · 19 hydrogen bonds · protein-protein
  • A–I · 708 Ų buried · 16 hydrogen bonds · protein-protein
  • A–M · 258 Ų buried · 4 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 8 disulfide (disulfide).

Compared structures

  • 4NP4 · Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.